Completed PHASE1 INTERVENTIONAL 1-arm NCT01446458

Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer

Phase I Study of Stereotactic Body Radiation Therapy and 5-Fluorouracil, Oxaliplatin and Irinotecan (FOLFIRINOX) in the Neoadjuvant Therapy of Pancreatic Cancer

Sponsor: Emory University

Conditions Cancer of Pancreas Cancer of the Pancreas Neoplasms, Pancreatic Pancreas Cancer Pancreas Neoplasms

Interventions Modified FOLFIRINOX Stereotactic Body Radiotherapy (SBRT)

Updated 6 times since 2017 Last updated: Mar 21, 2016 Started: Nov 30, 2011 Primary completion: Mar 31, 2015 Completion: Mar 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01446458, this PHASE1 trial focuses on Cancer of Pancreas and Cancer of the Pancreas and remains completed. Sponsored by Emory University, it has been updated 6 times since 2011, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Nov 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Emory University

Data source: Emory University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Atlanta, United States